Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series
Relapsed/refractory acute myeloid leukemia (R/R AML) carries a poor prognosis. We report three patients with R/R AML, each of whom had relapsed after at least two prior chemotherapy regimens or hematopoietic stem-cell transplantation (HSCT), treated with chidamide, decitabine, venetoclax, and low-do...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2026-02-01
|
| Colección: | Frontiers in Oncology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1760614/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|